We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





Urine Test to Measure Specific Biomarkers of COVID-19 Patients’ Immune System Could Predict Disease Severity

By LabMedica International staff writers
Posted on 29 Apr 2021
Print article
Illustration
Illustration
Urine analysis of COVID-19 patients revealed elevated levels of specific biomarkers of the immune system compared to those who were not infected with the coronavirus, suggesting that a urine test to measure these biomarkers could predict disease severity.

In addition, levels of these inflammatory markers were higher in patients with comorbidities such as high blood pressure and diabetes, according to researchers from Wayne State University (Detroit, MI, USA). Researchers said they undertook this study in hopes of determining whether biomarkers of COVID-19 could predict which individuals will develop "overly exuberant immune responses," also called a cytokine storm. They chose to screen the urine of COVID-19 patients because of its non-invasive nature that doesn't require the use of needles or blood samples.

Scientists said they hope the results of this study will translate to a regular screening process for COVID-19 patients to predict who is more likely to develop severe disease and to aid in a successful treatment strategy.

Related Links:
Wayne State University

Gold Supplier
Sample Transport
VACUETTE Transport Line
New
Gold Supplier
TRANSPORT MEDIUM
TRANSPORT MEDIUM-2
New
Influenza A/B Assay
Influenza A+B One Step Assay
New
Infant Heel Lancet
Unistik TinyTouch

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.